Valuation: Celsion Corporation

Market Cap 7.94M 6.94M 6.42M 5.89M 11.15M 765M 11.34M 76.56M 30.08M 374M 29.83M 29.17M 1.29B P/E 2026 *
-0.6x
P/E 2027 * -0.83x
Enterprise Value 7.94M 6.94M 6.42M 5.89M 11.15M 765M 11.34M 76.56M 30.08M 374M 29.83M 29.17M 1.29B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%+4.90%+61.15%+87.70% 57.82B
-0.05%-5.85%+54.36%+124.61% 53.71B
-2.14%-9.13%+2.74%+421.65% 23.8B
-0.47%-1.53%-18.61%-15.41% 23.26B
-0.31%+3.00%+38.16%-4.28% 20.7B
-0.29%-2.05%+34.41%-27.98% 17.81B
-4.55%-1.95%+192.65%+349.58% 16.9B
-0.57%+0.68%+35.28%+695.72% 16.36B
+0.23%-2.49%+24.26%+187.16% 13.96B
Average -1.30%+0.56%+47.16%+202.08% 27.15B
Weighted average by Cap. -1.48%-0.15%+47.73%+166.81%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.34M -13.26M -12.17M -23.03M -1.58B -23.44M -158M -62.14M -772M -61.62M -60.26M -2.67B -23.33M -20.39M -18.86M -17.3M -32.75M -2.25B -33.32M -225M -88.34M -1.1B -87.6M -85.68M -3.79B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-